

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

Security Code: 532815

Dear Sir/Madam,

Date: 16th September, 2019

The Manager,
Listing Compliance Department,
National Stock Exchange of India
Ltd. Exchange Plaza, Plot no. C/1, G
Block, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051.

CIN: L24239TG1987PLC008066

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad - 500 034, Telangana, INDIA.

Tel: +91-40-2525 9999, Fax: +91-40-2525 9889

Email: info@smspharma.com, www.smspharma.com

Symbol: SMSPHARMA

Sub: Clarification on Product information – Reg. Ref: US DMF information sought on - Ranitidine HCl.

This is to inform you that since USFDA is aware of NDMA (N-Nitrosodimethylamine) is present as an impurity in some Ranitidine API and drugs products. FDA has issued a "DMF information request" to M/s. SMS Pharmaceuticals Limited also to provide the information to demonstrate our Ranitidine API manufacturing process does not contain NDMA impurity.

Our technical team is evaluating Ranitidine manufacturing process and will furnish the FDA requested data within the time frame set to us.

We will update you as and when the information provided to the FDA.

Please take the same on your records.

Yours faithfully
For SMS PHARMACEUTICALS LIMITED

V S Venkatish

Company Secretary